pharma news today glp-1 obesity drugs today Dozens of new are coming: these are the ones to watch GLP-1 drugs transform obesity care,

The needles are typically quite thin and, therefore, less painful than you might expect

Curristin, S

Pfizer halted development of its oral GLP-1 danuglipron in 2025 after a trial participant developed liver injury, reflecting safety concerns that require ongoing monitoring with real-world data

Like Ozempic, it requires prior authorization and documentation of previous medication trials

These treatments are designed to replenish your natural levels, offering a range of beauty and wellness benefits

For supplement formulators, this represents a compelling formulation opportunity: a synergistic thyroid antioxidant complex combining Pure Glutathione Powder with selenomethionine or selenium-enriched yeast